Oncology
Intelligence Dashboard

An oncology intelligence dashboard integrating live ClinicalTrials.gov pipeline data with PubMed publication analytics. Tracks sponsor activity across clinical phases (Phase 1-3), maps molecular target landscapes (ADCs, IO, KRAS, Bishpecifics), identifies key opinion leaders through publication network analysis, and synthesizes strategic insights for high-stakes clinical development.

Oncology Pipeline AnalyticsADC & IO LandscapesPubMed E-utilitiesKOL Network MappingPhase 1-3 TrackingMolecular Target ExtractionD3 VisualizationsPrecision Medicine Insights

Data Sources: ClinicalTrials.gov API v2 (NLM), PubMed E-utilities, CMS Open Payments, NPPES NPI Registry. Data synchronized via scheduled Cloudflare Worker cycles.

63,525

Oncology Trials

Phase 1–3 · ClinicalTrials.gov

~16,000

US Oncologists

NPI Registry · All subspecialties

318,856

Preprints Indexed

bioRxiv cumulative

~14 hrs

Warehouse Refresh

5 cats/run · every 2h cron

Global Overview

Targets & Modalities

Solid Tumors & Heme

Last RefreshedNever

Loading module...

Oncology CI Architecture

Oncology Data Pipeline

ClinicalTrials.gov v2 API provides structured trial data. PubMed E-utilities supply publication metadata. Both sources are transformed client-side with advanced oncology target extraction (e.g., TROP2, CLDN18.2, HER2) via keyword matching against intervention names and trial descriptions.

Strategic State Management

React Context + useReducer manages cross-tab state: trial/publication data, tracked oncology sponsors, active filters, and view selections. Action types handle dynamic data loading, oncology-specific filtering, and cross-tab interactions for KOL mapping.

Visual Intelligence

D3 sub-packages compute layouts for co-authorship networks and competitive density heatmaps. Recharts handles oncology pipeline treemaps and enrollment bars. All visualizations use a high-contrast clinical teal and slate palette for professional scanning.

Oncology Landmark References

ClinicalTrials.gov API v2. U.S. National Library of Medicine. https://clinicaltrials.gov/data-api/api
Modi S, et al. Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer (DESTINY-Breast04). N Engl J Med. 2022.
Bardia A, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (ASCENT). N Engl J Med. 2021.
Abou-Alfa GK, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy). Lancet Oncol. 2020.
Oh D-Y, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1). NEJM Evid. 2022.
Powell MA, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer (SORAYA). J Clin Oncol. 2023.

OncologyIntelligence Dashboard